{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:07:42Z","timestamp":1794377262318,"version":"4.9.0"},"reference-count":211,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natural Science Foundation of china","award":["81700306"],"award-info":[{"award-number":["81700306"]}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2026JJ50095"],"award-info":[{"award-number":["2026JJ50095"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Clinical Specialty Scientific Research Project","award":["Z2023006"],"award-info":[{"award-number":["Z2023006"]}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0528200"],"award-info":[{"award-number":["2024ZD0528200"]}]},{"name":"Innovation Platform and Talent Program","award":["2023TP1047"],"award-info":[{"award-number":["2023TP1047"]}]},{"name":"Scientific Research Project of the Education Department of Hunan Province","award":["25A0335"],"award-info":[{"award-number":["25A0335"]}],"id":[{"id":"https:\/\/ror.org\/05ckg3w11","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Hengyang Science and Technology Innovation Program","award":["202550038088"],"award-info":[{"award-number":["202550038088"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiac fibrosis is a critical pathological process driving the progression of heart failure, characterized by excessive extracellular matrix deposition, collagen network remodeling, and expansion of the myocardial interstitium. While fibrosis may reflect a reparative response to tissue injury, it can also signify a maladaptive remodeling process that progressively impairs cardiac structure and function. Cardiac fibroblasts and myofibroblasts serve as the principal effector cells responsible for matrix accumulation, whereas cardiomyocytes and immune cells contribute to fibrotic expansion through inflammatory signaling, paracrine communication, and microenvironmental regulation. Transforming growth factor-\u03b2, the renin\u2013angiotensin\u2013aldosterone system, inflammatory cytokines, mechanical stress, and metabolic disturbances collectively orchestrate a profibrotic signaling network. By regulating extracellular matrix synthesis, degradation, and crosslinking, these pathways promote myocardial stiffening and functional decompensation. In this review, we discuss the histopathological patterns of cardiac fibrosis across various pathological contexts, the major cellular contributors, and the core molecular mechanisms involved, while summarizing current advances in diagnostic evaluation and translational therapeutic strategies. We further discuss the context-dependent role of sirtuin 3 (SIRT3), a mitochondrial nicotinamide adenine dinucleotide (NAD\u207a)-dependent deacetylase, in linking mitochondrial homeostasis, oxidative stress, metabolic adaptation, and profibrotic signaling. More precise antifibrotic strategies require better definition of fibroblast states, fibrosis activity, and disease-specific remodeling patterns.<\/jats:p>","DOI":"10.1186\/s43556-026-00587-1","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:04:01Z","timestamp":1789527841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiac fibrosis: mechanistic insights and translational advances"],"prefix":"10.1186","volume":"7","author":[{"given":"Hui-Yi","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ting","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Heng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Xi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Fang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3842-1666","authenticated-orcid":false,"given":"Heng-Jing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"6","key":"587_CR1","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","volume":"117","author":"NG Frangogiannis","year":"2021","unstructured":"Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res. 2021;117(6):1450\u201388. https:\/\/doi.org\/10.1093\/cvr\/cvaa324.","journal-title":"Cardiovasc Res"},{"key":"587_CR2","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3389\/fphys.2018.01094","volume":"9","author":"RM Parodi-Rull\u00e1n","year":"2018","unstructured":"Parodi-Rull\u00e1n RM, Chapa-Dubocq XR, Javadov S. Acetylation of mitochondrial proteins in the heart: the role of SIRT3. Front Physiol. 2018;9:1094. https:\/\/doi.org\/10.3389\/fphys.2018.01094.","journal-title":"Front Physiol"},{"key":"587_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.850340","volume":"9","author":"K Murugasamy","year":"2022","unstructured":"Murugasamy K, Munjal A, Sundaresan NR. Emerging roles of SIRT3 in cardiac metabolism. Front Cardiovasc Med. 2022;9:850340. https:\/\/doi.org\/10.3389\/fcvm.2022.850340.","journal-title":"Front Cardiovasc Med"},{"issue":"24","key":"587_CR4","doi-asserted-by":"publisher","first-page":"8807","DOI":"10.1128\/MCB.01636-07","volume":"27","author":"DB Lombard","year":"2007","unstructured":"Lombard DB, Alt FW, Cheng H-L, Bunkenborg J, Streeper RS, Mostoslavsky R, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol. 2007;27(24):8807\u201314. https:\/\/doi.org\/10.1128\/MCB.01636-07.","journal-title":"Mol Cell Biol"},{"key":"587_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116004","volume":"170","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Zhou S, Chang X, Liu R. SIRT3 regulates mitochondrial function: a promising star target for cardiovascular disease therapy. Biomed Pharmacother. 2024;170:116004. https:\/\/doi.org\/10.1016\/j.biopha.2023.116004.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"587_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00441-016-2431-9","volume":"365","author":"V Talman","year":"2016","unstructured":"Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 2016;365(3):563\u201381. https:\/\/doi.org\/10.1007\/s00441-016-2431-9.","journal-title":"Cell Tissue Res"},{"issue":"5","key":"587_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","volume":"11","author":"NG Frangogiannis","year":"2014","unstructured":"Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11(5):255\u201365. https:\/\/doi.org\/10.1038\/nrcardio.2014.28.","journal-title":"Nat Rev Cardiol"},{"issue":"1\u20133","key":"587_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.pbiomolbio.2015.11.002","volume":"120","author":"JW Holmes","year":"2016","unstructured":"Holmes JW, Laksman Z, Gepstein L. Making better scar: emerging approaches for modifying mechanical and electrical properties following infarction and ablation. Prog Biophys Mol Biol. 2016;120(1\u20133):134\u201348. https:\/\/doi.org\/10.1016\/j.pbiomolbio.2015.11.002.","journal-title":"Prog Biophys Mol Biol"},{"issue":"2","key":"587_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1161\/HYPERTENSIONAHA.123.21708","volume":"81","author":"A Gonz\u00e1lez","year":"2024","unstructured":"Gonz\u00e1lez A, L\u00f3pez B, Ravassa S, San Jos\u00e9 G, Latasa I, Butler J, et al. Myocardial interstitial fibrosis in hypertensive heart disease: From mechanisms to clinical management. Hypertension. 2024;81(2):218\u201328. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.123.21708.","journal-title":"Hypertension"},{"issue":"Suppl C","key":"587_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/eurheartj\/16.suppl_c.24","volume":"16","author":"KT Weber","year":"1995","unstructured":"Weber KT, Sun Y, Guarda E, Katwa LC, Ratajska A, Cleutjens JP, et al. Myocardial fibrosis in hypertensive heart disease: An overview of potential regulatory mechanisms. Eur Heart J. 1995;16(Suppl C):24\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/16.suppl_c.24.","journal-title":"Eur Heart J"},{"issue":"4","key":"587_CR11","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/01.HYP.0000118584.33350.7D","volume":"43","author":"F Kuwahara","year":"2004","unstructured":"Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, et al. Hypertensive myocardial fibrosis and diastolic dysfunction: Another model of inflammation? Hypertension. 2004;43(4):739\u201345. https:\/\/doi.org\/10.1161\/01.HYP.0000118584.33350.7D.","journal-title":"Hypertension"},{"issue":"3","key":"587_CR12","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1161\/HYPERTENSIONAHA.118.11125","volume":"72","author":"A Gonz\u00e1lez","year":"2018","unstructured":"Gonz\u00e1lez A, Ravassa S, L\u00f3pez B, Moreno MU, Beaumont J, San Jos\u00e9 G, et al. Myocardial remodeling in hypertension. Hypertension. 2018;72(3):549\u201358. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11125.","journal-title":"Hypertension"},{"key":"587_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.yjmcc.2015.12.011","volume":"90","author":"I Russo","year":"2016","unstructured":"Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol. 2016;90:84\u201393. https:\/\/doi.org\/10.1016\/j.yjmcc.2015.12.011.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"587_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13098-025-01783-9","volume":"17","author":"J Sun","year":"2025","unstructured":"Sun J, Zhou R, Liu M, Zhang D. The role of myocardial fibrosis in the diabetic cardiomyopathy. Diabetol Metab Syndr. 2025;17(1):242. https:\/\/doi.org\/10.1186\/s13098-025-01783-9.","journal-title":"Diabetol Metab Syndr"},{"key":"587_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113904","volume":"176","author":"I Tuleta","year":"2021","unstructured":"Tuleta I, Frangogiannis NG. Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities. Adv Drug Deliv Rev. 2021;176:113904. https:\/\/doi.org\/10.1016\/j.addr.2021.113904.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"587_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.092.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"587_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.14336\/AD.2022.0523","volume":"14","author":"Z Cai","year":"2023","unstructured":"Cai Z, Wu C, Xu Y, Cai J, Zhao M, Zu L. The NO-cGMP-PKG axis in HFpEF: from pathological mechanisms to potential therapies. Aging Dis. 2023;14(1):46\u201362. https:\/\/doi.org\/10.14336\/AD.2022.0523.","journal-title":"Aging Dis"},{"issue":"10","key":"587_CR18","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","volume":"128","author":"WJ Paulus","year":"2021","unstructured":"Paulus WJ, Zile MR. From systemic inflammation to myocardial fibrosis: The heart failure with preserved ejection fraction paradigm revisited. Circ Res. 2021;128(10):1451\u201367. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318159.","journal-title":"Circ Res"},{"issue":"2","key":"587_CR19","first-page":"158","volume":"2","author":"A Biernacka","year":"2011","unstructured":"Biernacka A, Frangogiannis NG. Aging and cardiac fibrosis. Aging Dis. 2011;2(2):158\u201373.","journal-title":"Aging Dis"},{"key":"587_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1146\/annurev-physiol-021119-034527","volume":"82","author":"MD Tallquist","year":"2020","unstructured":"Tallquist MD. Cardiac fibroblast diversity. Annu Rev Physiol. 2020;82:63\u201378. https:\/\/doi.org\/10.1146\/annurev-physiol-021119-034527.","journal-title":"Annu Rev Physiol"},{"issue":"12","key":"587_CR21","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1161\/CIRCRESAHA.109.209809","volume":"105","author":"CA Souders","year":"2009","unstructured":"Souders CA, Bowers SLK, Baudino TA. Cardiac fibroblast: the renaissance cell. Circ Res. 2009;105(12):1164\u201376. https:\/\/doi.org\/10.1161\/CIRCRESAHA.109.209809.","journal-title":"Circ Res"},{"key":"587_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.609653","volume":"8","author":"M D\u2019Urso","year":"2020","unstructured":"D\u2019Urso M, Kurniawan NA. Mechanical and physical regulation of fibroblast-myofibroblast transition: from cellular mechanoresponse to tissue pathology. Front Bioeng Biotechnol. 2020;8:609653. https:\/\/doi.org\/10.3389\/fbioe.2020.609653.","journal-title":"Front Bioeng Biotechnol"},{"issue":"4","key":"587_CR23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/FJC.0b013e31820cda19","volume":"57","author":"C Vasquez","year":"2011","unstructured":"Vasquez C, Benamer N, Morley GE. The cardiac fibroblast: Functional and electrophysiological considerations in healthy and diseased hearts. J Cardiovasc Pharmacol. 2011;57(4):380\u20138. https:\/\/doi.org\/10.1097\/FJC.0b013e31820cda19.","journal-title":"J Cardiovasc Pharmacol"},{"key":"587_CR24","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.43882","volume":"8","author":"N Farbehi","year":"2019","unstructured":"Farbehi N, Patrick R, Dorison A, Xaymardan M, Janbandhu V, Wystub-Lis K, et al. Single-cell expression profiling reveals dynamic flux of cardiac stromal, vascular and immune cells in health and injury. Elife. 2019;8:e43882. https:\/\/doi.org\/10.7554\/eLife.43882.","journal-title":"Elife"},{"issue":"5","key":"587_CR25","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1172\/JCI98215","volume":"128","author":"X Fu","year":"2018","unstructured":"Fu X, Khalil H, Kanisicak O, Boyer JG, Vagnozzi RJ, Maliken BD, et al. Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart. J Clin Invest. 2018;128(5):2127\u201343. https:\/\/doi.org\/10.1172\/JCI98215.","journal-title":"J Clin Invest"},{"key":"587_CR26","doi-asserted-by":"publisher","first-page":"12260","DOI":"10.1038\/ncomms12260","volume":"7","author":"O Kanisicak","year":"2016","unstructured":"Kanisicak O, Khalil H, Ivey MJ, Karch J, Maliken BD, Correll RN, et al. Genetic lineage tracing defines myofibroblast origin and function in the injured heart. Nat Commun. 2016;7:12260. https:\/\/doi.org\/10.1038\/ncomms12260.","journal-title":"Nat Commun"},{"issue":"1","key":"587_CR27","doi-asserted-by":"publisher","first-page":"11660","DOI":"10.1038\/s41467-025-66597-9","volume":"16","author":"LP Aguado-Alvaro","year":"2025","unstructured":"Aguado-Alvaro LP, Garitano N, Esser-Skala W, Sayers J, Del Valle C, Alameda D, et al. Identification of epigenetic regulators of fibrotic transformation in cardiac fibroblasts through bulk and single-cell CRISPR screens. Nat Commun. 2025;16(1):11660. https:\/\/doi.org\/10.1038\/s41467-025-66597-9.","journal-title":"Nat Commun"},{"issue":"10","key":"587_CR28","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1038\/s44321-025-00305-4","volume":"17","author":"C Zhu","year":"2025","unstructured":"Zhu C, Hong W, Zhu Y, Xue Y, Fang Z, Jiang D, et al. TET3 is a regulator and can be targeted for the intervention of myocardial fibrosis. EMBO Mol Med. 2025;17(10):2809\u201326. https:\/\/doi.org\/10.1038\/s44321-025-00305-4.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"587_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/cvr\/cvae243","volume":"121","author":"G Senesi","year":"2025","unstructured":"Senesi G, Lodrini AM, Mohammed S, Mosole S, Hjortnaes J, Veltrop RJA, et al. miR-24-3p secreted as extracellular vesicle cargo by cardiomyocytes inhibits fibrosis in human cardiac microtissues. Cardiovasc Res. 2025;121(1):143\u201356. https:\/\/doi.org\/10.1093\/cvr\/cvae243.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"587_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.001993","volume":"4","author":"W Zhang","year":"2015","unstructured":"Zhang W, Lavine KJ, Epelman S, Evans SA, Weinheimer CJ, Barger PM, et al. Necrotic myocardial cells release damage-associated molecular patterns that provoke fibroblast activation in vitro and trigger myocardial inflammation and fibrosis in vivo. J Am Heart Assoc. 2015;4(6):e001993. https:\/\/doi.org\/10.1161\/JAHA.115.001993.","journal-title":"J Am Heart Assoc"},{"key":"587_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.yjmcc.2015.11.002","volume":"94","author":"NA Turner","year":"2016","unstructured":"Turner NA. Inflammatory and fibrotic responses of cardiac fibroblasts to myocardial damage associated molecular patterns (DAMPs). J Mol Cell Cardiol. 2016;94:189\u2013200. https:\/\/doi.org\/10.1016\/j.yjmcc.2015.11.002.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"587_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jacbts.2024.06.003","volume":"10","author":"X-Z Zhang","year":"2025","unstructured":"Zhang X-Z, Li Q-L, Tang T-T, Cheng X. Emerging role of macrophage-fibroblast interactions in cardiac homeostasis and remodeling. JACC Basic Transl Sci. 2025;10(1):113\u201327. https:\/\/doi.org\/10.1016\/j.jacbts.2024.06.003.","journal-title":"JACC Basic Transl Sci"},{"issue":"8038","key":"587_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41586-024-08008-5","volume":"635","author":"JM Amrute","year":"2024","unstructured":"Amrute JM, Luo X, Penna V, Yang S, Yamawaki T, Hayat S, et al. Targeting immune-fibroblast cell communication in heart failure. Nature. 2024;635(8038):423\u201333. https:\/\/doi.org\/10.1038\/s41586-024-08008-5.","journal-title":"Nature"},{"issue":"25","key":"587_CR34","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1016\/j.jacc.2019.10.036","volume":"74","author":"N Haider","year":"2019","unstructured":"Haider N, Bosc\u00e1 L, Zandbergen HR, Kovacic JC, Narula N, Gonz\u00e1lez-Ramos S, et al. Transition of macrophages to fibroblast-like cells in healing myocardial infarction. J Am Coll Cardiol. 2019;74(25):3124\u201335. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.036.","journal-title":"J Am Coll Cardiol"},{"key":"587_CR35","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.yjmcc.2024.07.010","volume":"196","author":"R Li","year":"2024","unstructured":"Li R, Hanna A, Huang S, Hernandez SC, Tuleta I, Kubota A, et al. Macrophages in the infarcted heart acquire a fibrogenic phenotype, expressing matricellular proteins, but do not undergo fibroblast conversion. J Mol Cell Cardiol. 2024;196:152\u201367. https:\/\/doi.org\/10.1016\/j.yjmcc.2024.07.010.","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"587_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112131","volume":"42","author":"K Hoeft","year":"2023","unstructured":"Hoeft K, Schaefer GJL, Kim H, Schumacher D, Bleckwehl T, Long Q, et al. Platelet-instructed SPP1+ macrophages drive myofibroblast activation in fibrosis in a CXCL4-dependent manner. Cell Rep. 2023;42(2):112131. https:\/\/doi.org\/10.1016\/j.celrep.2023.112131.","journal-title":"Cell Rep"},{"issue":"4","key":"587_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-020-0798-y","volume":"115","author":"I Cuijpers","year":"2020","unstructured":"Cuijpers I, Simmonds SJ, van Bilsen M, Czarnowska E, Gonz\u00e1lez Miqueo A, Heymans S, et al. Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities. Basic Res Cardiol. 2020;115(4):39. https:\/\/doi.org\/10.1007\/s00395-020-0798-y.","journal-title":"Basic Res Cardiol"},{"issue":"6","key":"587_CR38","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/cvr\/cvae044","volume":"120","author":"K Torimoto","year":"2024","unstructured":"Torimoto K, Elliott K, Nakayama Y, Yanagisawa H, Eguchi S. Cardiac and perivascular myofibroblasts, matrifibrocytes, and immune fibrocytes in hypertension; commonalities and differences with other cardiovascular diseases. Cardiovasc Res. 2024;120(6):567\u201380. https:\/\/doi.org\/10.1093\/cvr\/cvae044.","journal-title":"Cardiovasc Res"},{"issue":"1\u20132","key":"587_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/14728222.2024.2316735","volume":"28","author":"NG Frangogiannis","year":"2024","unstructured":"Frangogiannis NG. TGF-\u03b2 as a therapeutic target in the infarcted and failing heart: cellular mechanisms, challenges, and opportunities. Expert Opin Ther Targets. 2024;28(1\u20132):45\u201356. https:\/\/doi.org\/10.1080\/14728222.2024.2316735.","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"587_CR40","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/s0092-8674(03)00432-x","volume":"113","author":"Y Shi","year":"2003","unstructured":"Shi Y, Massagu\u00e9 J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113(6):685\u2013700. https:\/\/doi.org\/10.1016\/s0092-8674(03)00432-x.","journal-title":"Cell"},{"issue":"4","key":"587_CR41","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.yjmcc.2010.10.033","volume":"51","author":"M Dobaczewski","year":"2011","unstructured":"Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-\u03b2 signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51(4):600\u20136. https:\/\/doi.org\/10.1016\/j.yjmcc.2010.10.033.","journal-title":"J Mol Cell Cardiol"},{"key":"587_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102207","volume":"64","author":"C Humeres","year":"2022","unstructured":"Humeres C, Venugopal H, Frangogiannis NG. Smad-dependent pathways in the infarcted and failing heart. Curr Opin Pharmacol. 2022;64:102207. https:\/\/doi.org\/10.1016\/j.coph.2022.102207.","journal-title":"Curr Opin Pharmacol"},{"issue":"16","key":"587_CR43","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/cvr\/cvae210","volume":"120","author":"I Tuleta","year":"2024","unstructured":"Tuleta I, Hanna A, Humeres C, Aguilan JT, Sidoli S, Zhu F, et al. Fibroblast-specific TGF-\u03b2 signaling mediates cardiac dysfunction, fibrosis, and hypertrophy in obese diabetic mice. Cardiovasc Res. 2024;120(16):2047\u201363. https:\/\/doi.org\/10.1093\/cvr\/cvae210.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"587_CR44","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1161\/CIRCRESAHA.123.323360","volume":"135","author":"C Humeres","year":"2024","unstructured":"Humeres C, Shinde AV, Tuleta I, Hernandez SC, Hanna A, Huang S, et al. Fibroblast Smad7 induction protects the remodeling pressure-overloaded heart. Circ Res. 2024;135(3):453\u201369. https:\/\/doi.org\/10.1161\/CIRCRESAHA.123.323360.","journal-title":"Circ Res"},{"issue":"7","key":"587_CR45","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s44161-024-00502-3","volume":"3","author":"MP Lazaropoulos","year":"2024","unstructured":"Lazaropoulos MP, Gibb AA, Chapski DJ, Nair AA, Reiter AN, Roy R, et al. Nuclear ATP-citrate lyase regulates chromatin-dependent activation and maintenance of the myofibroblast gene program. Nat Cardiovasc Res. 2024;3(7):869\u201382. https:\/\/doi.org\/10.1038\/s44161-024-00502-3.","journal-title":"Nat Cardiovasc Res"},{"issue":"20","key":"587_CR46","doi-asserted-by":"publisher","first-page":"15472","DOI":"10.3390\/ijms242015472","volume":"24","author":"AA Manolis","year":"2023","unstructured":"Manolis AA, Manolis TA, Manolis AS. Neurohumoral activation in heart failure. Int J Mol Sci. 2023;24(20):15472. https:\/\/doi.org\/10.3390\/ijms242015472.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"587_CR47","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/j.1476-5381.2010.00750.x","volume":"160","author":"TKW Ma","year":"2010","unstructured":"Ma TKW, Kam KKH, Yan BP, Lam Y-Y. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010;160(6):1273\u201392. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00750.x.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"587_CR48","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.yjmcc.2009.08.002","volume":"48","author":"Y Sun","year":"2010","unstructured":"Sun Y. Intracardiac renin-angiotensin system and myocardial repair\/remodeling following infarction. J Mol Cell Cardiol. 2010;48(3):483\u20139. https:\/\/doi.org\/10.1016\/j.yjmcc.2009.08.002.","journal-title":"J Mol Cell Cardiol"},{"key":"587_CR49","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fendo.2014.00016","volume":"5","author":"WC De Mello","year":"2014","unstructured":"De Mello WC, Frohlich ED. Clinical perspectives and fundamental aspects of local cardiovascular and renal renin-angiotensin systems. Front Endocrinol (Lausanne). 2014;5:16. https:\/\/doi.org\/10.3389\/fendo.2014.00016.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"587_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3317\/jraas.2001.012","volume":"2","author":"PJ Lijnen","year":"2001","unstructured":"Lijnen PJ, Petrov VV, Fagard RH. Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors. J Renin Angiotensin Aldosterone Syst. 2001;2(2):117\u201322. https:\/\/doi.org\/10.3317\/jraas.2001.012.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"1","key":"587_CR51","doi-asserted-by":"publisher","first-page":"H176","DOI":"10.1152\/ajpheart.00421.2002","volume":"284","author":"JD Stockand","year":"2003","unstructured":"Stockand JD, Meszaros JG. Aldosterone stimulates proliferation of cardiac fibroblasts by activating ki-RasA and MAPK1\/2 signaling. Am J Physiol Heart Circ Physiol. 2003;284(1):H176\u201384. https:\/\/doi.org\/10.1152\/ajpheart.00421.2002.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"8","key":"587_CR52","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrneph.2013.110","volume":"9","author":"NJ Brown","year":"2013","unstructured":"Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013;9(8):459\u201369. https:\/\/doi.org\/10.1038\/nrneph.2013.110.","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"587_CR53","doi-asserted-by":"publisher","first-page":"6972","DOI":"10.3390\/ijms24086972","volume":"24","author":"R Duangrat","year":"2023","unstructured":"Duangrat R, Parichatikanond W, Mangmool S. Dual blockade of TGF-\u03b2 receptor and endothelin receptor synergistically inhibits angiotensin II-induced myofibroblast differentiation: role of AT1R\/g\u03b1q-mediated TGF-\u03b21 and ET-1 signaling. Int J Mol Sci. 2023;24(8):6972. https:\/\/doi.org\/10.3390\/ijms24086972.","journal-title":"Int J Mol Sci"},{"key":"587_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175780","volume":"951","author":"W Parichatikanond","year":"2023","unstructured":"Parichatikanond W, Duangrat R, Mangmool S. G\u03b1q protein-biased ligand of angiotensin II type 1 receptor mediates myofibroblast differentiation through TGF-\u03b21\/ERK axis in human cardiac fibroblasts. Eur J Pharmacol. 2023;951:175780. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175780.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"587_CR55","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1038\/s41467-023-40639-6","volume":"14","author":"Z-G Ma","year":"2023","unstructured":"Ma Z-G, Yuan Y-P, Fan D, Zhang X, Teng T, Song P, et al. IRX2 regulates angiotensin II-induced cardiac fibrosis by transcriptionally activating EGR1 in Male mice. Nat Commun. 2023;14(1):4967. https:\/\/doi.org\/10.1038\/s41467-023-40639-6.","journal-title":"Nat Commun"},{"issue":"6","key":"587_CR56","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1006\/jmcc.2000.1129","volume":"32","author":"P Lijnen","year":"2000","unstructured":"Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol. 2000;32(6):865\u201379. https:\/\/doi.org\/10.1006\/jmcc.2000.1129.","journal-title":"J Mol Cell Cardiol"},{"issue":"7","key":"587_CR57","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1210\/en.2011-2098","volume":"153","author":"LA Bienvenu","year":"2012","unstructured":"Bienvenu LA, Morgan J, Rickard AJ, Tesch GH, Cranston GA, Fletcher EK, et al. Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology. 2012;153(7):3416\u201325. https:\/\/doi.org\/10.1210\/en.2011-2098.","journal-title":"Endocrinology"},{"issue":"6","key":"587_CR58","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1161\/HYPERTENSIONAHA.112.203158","volume":"60","author":"AJ Rickard","year":"2012","unstructured":"Rickard AJ, Morgan J, Bienvenu LA, Fletcher EK, Cranston GA, Shen JZ, et al. Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone\/salt-mediated inflammation and cardiac fibrosis. Hypertension. 2012;60(6):1443\u201350. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.112.203158.","journal-title":"Hypertension"},{"issue":"3","key":"587_CR59","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.109.131110","volume":"54","author":"AJ Rickard","year":"2009","unstructured":"Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone\/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009;54(3):537\u201343. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.131110.","journal-title":"Hypertension"},{"issue":"1","key":"587_CR60","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1161\/HYPERTENSIONAHA.117.09070","volume":"70","author":"C Li","year":"2017","unstructured":"Li C, Sun X-N, Zeng M-R, Zheng X-J, Zhang Y-Y, Wan Q, et al. Mineralocorticoid receptor deficiency in T cells attenuates pressure overload-induced cardiac hypertrophy and dysfunction through modulating T-cell activation. Hypertension. 2017;70(1):137\u201347. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.09070.","journal-title":"Hypertension"},{"issue":"5","key":"587_CR61","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1161\/HYPERTENSIONAHA.123.21364","volume":"81","author":"M Bader","year":"2024","unstructured":"Bader M, Steckelings UM, Alenina N, Santos RAS, Ferrario CM. Alternative renin-angiotensin system. Hypertension. 2024;81(5):964\u201376. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.123.21364.","journal-title":"Hypertension"},{"issue":"2","key":"587_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2023.151288","volume":"102","author":"G Tian","year":"2023","unstructured":"Tian G, Ren T. Mechanical stress regulates the mechanotransduction and metabolism of cardiac fibroblasts in fibrotic cardiac diseases. Eur J Cell Biol. 2023;102(2):151288. https:\/\/doi.org\/10.1016\/j.ejcb.2023.151288.","journal-title":"Eur J Cell Biol"},{"issue":"5","key":"587_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6050053","volume":"6","author":"KM Herum","year":"2017","unstructured":"Herum KM, Lunde IG, McCulloch AD, Christensen G. The soft- and hard-heartedness of cardiac fibroblasts: mechanotransduction signaling pathways in fibrosis of the heart. J Clin Med. 2017;6(5):53. https:\/\/doi.org\/10.3390\/jcm6050053.","journal-title":"J Clin Med"},{"key":"587_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yjmcc.2022.07.006","volume":"172","author":"R Li","year":"2022","unstructured":"Li R, Frangogiannis NG. Integrins in cardiac fibrosis. J Mol Cell Cardiol. 2022;172:1\u201313. https:\/\/doi.org\/10.1016\/j.yjmcc.2022.07.006.","journal-title":"J Mol Cell Cardiol"},{"key":"587_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2023.149360","volume":"692","author":"Y-W Chen","year":"2024","unstructured":"Chen Y-W, Cheng P-P, Yin Y-F, Cai H, Chen J-Z, Feng M-H, et al. Integrin \u03b1V mediated activation of myofibroblast via mechanoparacrine of transforming growth factor \u03b21 in promoting fibrous scar formation after myocardial infarction. Biochem Biophys Res Commun. 2024;692:149360. https:\/\/doi.org\/10.1016\/j.bbrc.2023.149360.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"587_CR66","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/cvr\/cvu053","volume":"102","author":"V Sarrazy","year":"2014","unstructured":"Sarrazy V, Koehler A, Chow ML, Zimina E, Li CX, Kato H, et al. Integrins \u03b1v\u03b25 and \u03b1v\u03b23 promote latent TGF-\u03b21 activation by human cardiac fibroblast contraction. Cardiovasc Res. 2014;102(3):407\u201317. https:\/\/doi.org\/10.1093\/cvr\/cvu053.","journal-title":"Cardiovasc Res"},{"key":"587_CR67","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.actbio.2022.08.063","volume":"152","author":"S Ragazzini","year":"2022","unstructured":"Ragazzini S, Scocozza F, Bernava G, Auricchio F, Colombo GI, Barbuto M, et al. Mechanosensor YAP cooperates with TGF-\u03b21 signaling to promote myofibroblast activation and matrix stiffening in a 3D model of human cardiac fibrosis. Acta Biomater. 2022;152:300\u201312. https:\/\/doi.org\/10.1016\/j.actbio.2022.08.063.","journal-title":"Acta Biomater"},{"issue":"7","key":"587_CR68","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/cvr\/cvab205","volume":"118","author":"MM Mia","year":"2022","unstructured":"Mia MM, Cibi DM, Ghani SABA, Singh A, Tee N, Sivakumar V, et al. Loss of yap\/taz in cardiac fibroblasts attenuates adverse remodelling and improves cardiac function. Cardiovasc Res. 2022;118(7):1785\u2013804. https:\/\/doi.org\/10.1093\/cvr\/cvab205.","journal-title":"Cardiovasc Res"},{"issue":"9","key":"587_CR69","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jacbts.2020.07.009","volume":"5","author":"J Francisco","year":"2020","unstructured":"Francisco J, Zhang Y, Jeong JI, Mizushima W, Ikeda S, Ivessa A, et al. Blockade of fibroblast YAP attenuates cardiac fibrosis and dysfunction through MRTF-a inhibition. JACC Basic Transl Sci. 2020;5(9):931\u201345. https:\/\/doi.org\/10.1016\/j.jacbts.2020.07.009.","journal-title":"JACC Basic Transl Sci"},{"issue":"10","key":"587_CR70","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1074\/jbc.RA118.006123","volume":"294","author":"J Byun","year":"2019","unstructured":"Byun J, Del Re DP, Zhai P, Ikeda S, Shirakabe A, Mizushima W, et al. Yes-associated protein (YAP) mediates adaptive cardiac hypertrophy in response to pressure overload. J Biol Chem. 2019;294(10):3603\u201317. https:\/\/doi.org\/10.1074\/jbc.RA118.006123.","journal-title":"J Biol Chem"},{"issue":"6","key":"587_CR71","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150595","volume":"132","author":"T Kashihara","year":"2022","unstructured":"Kashihara T, Mukai R, Oka S-I, Zhai P, Nakada Y, Yang Z, et al. YAP mediates compensatory cardiac hypertrophy through aerobic glycolysis in response to pressure overload. J Clin Invest. 2022;132(6):e150595. https:\/\/doi.org\/10.1172\/JCI150595.","journal-title":"J Clin Invest"},{"issue":"3","key":"587_CR72","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI88759","volume":"127","author":"V Ramjee","year":"2017","unstructured":"Ramjee V, Li D, Manderfield LJ, Liu F, Engleka KA, Aghajanian H, et al. Epicardial YAP\/TAZ orchestrate an immunosuppressive response following myocardial infarction. J Clin Invest. 2017;127(3):899\u2013911. https:\/\/doi.org\/10.1172\/JCI88759.","journal-title":"J Clin Invest"},{"key":"587_CR73","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.yjmcc.2012.10.016","volume":"54","author":"RK Adapala","year":"2013","unstructured":"Adapala RK, Thoppil RJ, Luther DJ, Paruchuri S, Meszaros JG, Chilian WM, et al. TRPV4 channels mediate cardiac fibroblast differentiation by integrating mechanical and soluble signals. J Mol Cell Cardiol. 2013;54:45\u201352. https:\/\/doi.org\/10.1016\/j.yjmcc.2012.10.016.","journal-title":"J Mol Cell Cardiol"},{"issue":"15","key":"587_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158065","volume":"23","author":"N Braidotti","year":"2022","unstructured":"Braidotti N, Chen SN, Long CS, Cojoc D, Sbaizero O. Piezo1 channel as a potential target for hindering cardiac fibrotic remodeling. Int J Mol Sci. 2022;23(15):8065. https:\/\/doi.org\/10.3390\/ijms23158065.","journal-title":"Int J Mol Sci"},{"issue":"46","key":"587_CR75","doi-asserted-by":"publisher","first-page":"17395","DOI":"10.1074\/jbc.RA119.009167","volume":"294","author":"NM Blythe","year":"2019","unstructured":"Blythe NM, Muraki K, Ludlow MJ, Stylianidis V, Gilbert HTJ, Evans EL, et al. Mechanically activated Piezo1 channels of cardiac fibroblasts stimulate p38 mitogen-activated protein kinase activity and interleukin-6 secretion. J Biol Chem. 2019;294(46):17395\u2013408. https:\/\/doi.org\/10.1074\/jbc.RA119.009167.","journal-title":"J Biol Chem"},{"issue":"1","key":"587_CR76","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41421-022-00427-w","volume":"8","author":"L Niu","year":"2022","unstructured":"Niu L, Cheng B, Huang G, Nan K, Han S, Ren H, et al. A positive mechanobiological feedback loop controls bistable switching of cardiac fibroblast phenotype. Cell Discov. 2022;8(1):84. https:\/\/doi.org\/10.1038\/s41421-022-00427-w.","journal-title":"Cell Discov"},{"issue":"6","key":"587_CR77","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11886-023-01877-8","volume":"25","author":"A Hara","year":"2023","unstructured":"Hara A, Tallquist MD. Fibroblast and immune cell cross-talk in cardiac fibrosis. Curr Cardiol Rep. 2023;25(6):485\u201393. https:\/\/doi.org\/10.1007\/s11886-023-01877-8.","journal-title":"Curr Cardiol Rep"},{"key":"587_CR78","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.yjmcc.2015.11.016","volume":"93","author":"J Hartupee","year":"2016","unstructured":"Hartupee J, Mann DL. Role of inflammatory cells in fibroblast activation. J Mol Cell Cardiol. 2016;93:143\u20138. https:\/\/doi.org\/10.1016\/j.yjmcc.2015.11.016.","journal-title":"J Mol Cell Cardiol"},{"issue":"7","key":"587_CR79","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3390\/ijms20071599","volume":"20","author":"A Fiordelisi","year":"2019","unstructured":"Fiordelisi A, Iaccarino G, Morisco C, Coscioni E, Sorriento D. NFkappaB is a key player in the crosstalk between inflammation and cardiovascular diseases. Int J Mol Sci. 2019;20(7):1599. https:\/\/doi.org\/10.3390\/ijms20071599.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"587_CR80","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150161","volume":"6","author":"W Lu","year":"2021","unstructured":"Lu W, Meng Z, Hernandez R, Zhou C. Fibroblast-specific IKK-\u03b2 deficiency ameliorates angiotensin II-induced adverse cardiac remodeling in mice. JCI Insight. 2021;6(18):e150161. https:\/\/doi.org\/10.1172\/jci.insight.150161.","journal-title":"JCI Insight"},{"issue":"704","key":"587_CR81","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abe4932","volume":"14","author":"H Abe","year":"2021","unstructured":"Abe H, Tanada Y, Omiya S, Podaru M-N, Murakawa T, Ito J, et al. NF-\u03baB activation in cardiac fibroblasts results in the recruitment of inflammatory Ly6Chi monocytes in pressure-overloaded hearts. Sci Signal. 2021;14(704):eabe4932. https:\/\/doi.org\/10.1126\/scisignal.abe4932.","journal-title":"Sci Signal"},{"key":"587_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112219","volume":"143","author":"X Zhang","year":"2021","unstructured":"Zhang X, Qu H, Yang T, Kong X, Zhou H. Regulation and functions of NLRP3 inflammasome in cardiac fibrosis: current knowledge and clinical significance. Biomed Pharmacother. 2021;143:112219. https:\/\/doi.org\/10.1016\/j.biopha.2021.112219.","journal-title":"Biomed Pharmacother"},{"key":"587_CR83","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.2147\/JIR.S370483","volume":"15","author":"J Fan","year":"2022","unstructured":"Fan J, Ren M, Adhikari BK, Wang H, He Y. The NLRP3 inflammasome as a novel therapeutic target for cardiac fibrosis. J Inflamm Res. 2022;15:3847\u201358. https:\/\/doi.org\/10.2147\/JIR.S370483.","journal-title":"J Inflamm Res"},{"key":"587_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.04.022","volume":"74","author":"R Gao","year":"2019","unstructured":"Gao R, Shi H, Chang S, Gao Y, Li X, Lv C, et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. Int Immunopharmacol. 2019;74:105575. https:\/\/doi.org\/10.1016\/j.intimp.2019.04.022.","journal-title":"Int Immunopharmacol"},{"key":"587_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107133","volume":"90","author":"R-F Gao","year":"2021","unstructured":"Gao R-F, Li X, Xiang H-Y, Yang H, Lv C-Y, Sun X-L, et al. The covalent NLRP3-inflammasome inhibitor oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice. Int Immunopharmacol. 2021;90:107133. https:\/\/doi.org\/10.1016\/j.intimp.2020.107133.","journal-title":"Int Immunopharmacol"},{"issue":"14","key":"587_CR86","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1161\/01.cir.102.14.1690","volume":"102","author":"X Li","year":"2000","unstructured":"Li X, Moody MR, Engel D, Walker S, Clubb FJ, Sivasubramanian N, et al. Cardiac-specific overexpression of tumor necrosis factor-alpha causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation. 2000;102(14):1690\u20136. https:\/\/doi.org\/10.1161\/01.cir.102.14.1690.","journal-title":"Circulation"},{"issue":"23","key":"587_CR87","doi-asserted-by":"publisher","first-page":"12746","DOI":"10.1073\/pnas.97.23.12746","volume":"97","author":"YY Li","year":"2000","unstructured":"Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci U S A. 2000;97(23):12746\u201351. https:\/\/doi.org\/10.1073\/pnas.97.23.12746.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"587_CR88","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1161\/CIRCULATIONAHA.106.643585","volume":"115","author":"M Sun","year":"2007","unstructured":"Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation. 2007;115(11):1398\u2013407. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.643585.","journal-title":"Circulation"},{"issue":"8","key":"587_CR89","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/labinvest.2016.65","volume":"96","author":"J-H Wang","year":"2016","unstructured":"Wang J-H, Zhao L, Pan X, Chen N-N, Chen J, Gong Q-L, et al. Hypoxia-stimulated cardiac fibroblast production of IL-6 promotes myocardial fibrosis via the TGF-\u03b21 signaling pathway. Lab Invest. 2016;96(8):839\u201352. https:\/\/doi.org\/10.1038\/labinvest.2016.65.","journal-title":"Lab Invest"},{"issue":"2","key":"587_CR90","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1161\/HYPERTENSIONAHA.109.148635","volume":"56","author":"GC Mel\u00e9ndez","year":"2010","unstructured":"Mel\u00e9ndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010;56(2):225\u201331. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.148635.","journal-title":"Hypertension"},{"issue":"3","key":"587_CR91","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ijcard.2007.02.004","volume":"124","author":"P Timonen","year":"2008","unstructured":"Timonen P, Magga J, Risteli J, Punnonen K, Vanninen E, Turpeinen A, et al. Cytokines, interstitial collagen and ventricular remodelling in dilated cardiomyopathy. Int J Cardiol. 2008;124(3):293\u2013300. https:\/\/doi.org\/10.1016\/j.ijcard.2007.02.004.","journal-title":"Int J Cardiol"},{"key":"587_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.975367","volume":"13","author":"H Zhang","year":"2022","unstructured":"Zhang H, Yang K, Chen F, Liu Q, Ni J, Cao W, et al. Role of the CCL2-CCR2 axis in cardiovascular disease: pathogenesis and clinical implications. Front Immunol. 2022;13:975367. https:\/\/doi.org\/10.3389\/fimmu.2022.975367.","journal-title":"Front Immunol"},{"issue":"8","key":"587_CR93","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/s41591-018-0059-x","volume":"24","author":"G Bajpai","year":"2018","unstructured":"Bajpai G, Schneider C, Wong N, Bredemeyer A, Hulsmans M, Nahrendorf M, et al. The human heart contains distinct macrophage subsets with divergent origins and functions. Nat Med. 2018;24(8):1234\u201345. https:\/\/doi.org\/10.1038\/s41591-018-0059-x.","journal-title":"Nat Med"},{"issue":"6","key":"587_CR94","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41569-022-00823-5","volume":"20","author":"J Yap","year":"2023","unstructured":"Yap J, Irei J, Lozano-Gerona J, Vanapruks S, Bishop T, Boisvert WA. Macrophages in cardiac remodelling after myocardial infarction. Nat Rev Cardiol. 2023;20(6):373\u201385. https:\/\/doi.org\/10.1038\/s41569-022-00823-5.","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"587_CR95","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1161\/CIRCRESAHA.121.319737","volume":"129","author":"XS Revelo","year":"2021","unstructured":"Revelo XS, Parthiban P, Chen C, Barrow F, Fredrickson G, Wang H, et al. Cardiac resident macrophages prevent fibrosis and stimulate angiogenesis. Circ Res. 2021;129(12):1086\u2013101. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.319737.","journal-title":"Circ Res"},{"issue":"12","key":"587_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0355-7","volume":"51","author":"JN Peoples","year":"2019","unstructured":"Peoples JN, Saraf A, Ghazal N, Pham TT, Kwong JQ. Mitochondrial dysfunction and oxidative stress in heart disease. Exp Mol Med. 2019;51(12):1\u201313. https:\/\/doi.org\/10.1038\/s12276-019-0355-7.","journal-title":"Exp Mol Med"},{"issue":"9","key":"587_CR97","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1172\/JCI120849","volume":"128","author":"B Zhou","year":"2018","unstructured":"Zhou B, Tian R. Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Invest. 2018;128(9):3716\u201326. https:\/\/doi.org\/10.1172\/JCI120849.","journal-title":"J Clin Invest"},{"key":"587_CR98","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41420-020-00316-9","volume":"6","author":"X Li","year":"2020","unstructured":"Li X, Zhang W, Cao Q, Wang Z, Zhao M, Xu L, et al. Mitochondrial dysfunction in fibrotic diseases. Cell Death Discov. 2020;6:80. https:\/\/doi.org\/10.1038\/s41420-020-00316-9.","journal-title":"Cell Death Discov"},{"issue":"1","key":"587_CR99","doi-asserted-by":"publisher","first-page":"C53","DOI":"10.1152\/ajpcell.2001.280.1.C53","volume":"280","author":"DA Siwik","year":"2001","unstructured":"Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol. 2001;280(1):C53\u201360. https:\/\/doi.org\/10.1152\/ajpcell.2001.280.1.C53.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"9","key":"587_CR100","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1161\/01.RES.0000187457.24338.3D","volume":"97","author":"I Cucoranu","year":"2005","unstructured":"Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res. 2005;97(9):900\u20137. https:\/\/doi.org\/10.1161\/01.RES.0000187457.24338.3D.","journal-title":"Circ Res"},{"key":"587_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155626","volume":"145","author":"L-C Lin","year":"2023","unstructured":"Lin L-C, Tu B, Song K, Liu Z-Y, Sun H, Zhou Y, et al. Mitochondrial quality control in cardiac fibrosis: epigenetic mechanisms and therapeutic strategies. Metabolism. 2023;145:155626. https:\/\/doi.org\/10.1016\/j.metabol.2023.155626.","journal-title":"Metabolism"},{"issue":"1","key":"587_CR102","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90(1):207\u201358. https:\/\/doi.org\/10.1152\/physrev.00015.2009.","journal-title":"Physiol Rev"},{"issue":"8","key":"587_CR103","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41569-018-0044-6","volume":"15","author":"E Bertero","year":"2018","unstructured":"Bertero E, Maack C. Metabolic remodelling in heart failure. Nat Rev Cardiol. 2018;15(8):457\u201370. https:\/\/doi.org\/10.1038\/s41569-018-0044-6.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"587_CR104","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/cvr\/cvv105","volume":"106","author":"D Abdurrachim","year":"2015","unstructured":"Abdurrachim D, Luiken JJFP, Nicolay K, Glatz JFC, Prompers JJ, Nabben M. Good and bad consequences of altered fatty acid metabolism in heart failure: evidence from mouse models. Cardiovasc Res. 2015;106(2):194\u2013205. https:\/\/doi.org\/10.1093\/cvr\/cvv105.","journal-title":"Cardiovasc Res"},{"key":"587_CR105","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.matbio.2024.07.003","volume":"133","author":"J Guillard","year":"2024","unstructured":"Guillard J, Schw\u00f6rer S. Metabolic control of collagen synthesis. Matrix Biol. 2024;133:43\u201356. https:\/\/doi.org\/10.1016\/j.matbio.2024.07.003.","journal-title":"Matrix Biol"},{"issue":"2","key":"587_CR106","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000522417","volume":"8","author":"S Wang","year":"2022","unstructured":"Wang S, Liang Y, Dai C. Metabolic regulation of fibroblast activation and proliferation during organ fibrosis. Kidney Dis (Basel). 2022;8(2):115\u201325. https:\/\/doi.org\/10.1159\/000522417.","journal-title":"Kidney Dis (Basel)"},{"key":"587_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.701745","volume":"8","author":"Z-T Chen","year":"2021","unstructured":"Chen Z-T, Gao Q-Y, Wu M-X, Wang M, Sun R-L, Jiang Y, et al. Glycolysis inhibition alleviates cardiac fibrosis after myocardial infarction by suppressing cardiac fibroblast activation. Front Cardiovasc Med. 2021;8:701745. https:\/\/doi.org\/10.3389\/fcvm.2021.701745.","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"587_CR108","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00109-023-02323-6","volume":"101","author":"F Wang","year":"2023","unstructured":"Wang F, Yin X, Fan Y-M, Zhang X, Ma C, Jia K, et al. Upregulation of glycolytic enzyme PFKFB3 by deubiquitinase OTUD4 promotes cardiac fibrosis post myocardial infarction. J Mol Med (Berl). 2023;101(6):743\u201356. https:\/\/doi.org\/10.1007\/s00109-023-02323-6.","journal-title":"J Mol Med (Berl)"},{"issue":"21","key":"587_CR109","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.115.020226","volume":"133","author":"H Sun","year":"2016","unstructured":"Sun H, Olson KC, Gao C, Prosdocimo DA, Zhou M, Wang Z, et al. Catabolic defect of branched-chain amino acids promotes heart failure. Circulation. 2016;133(21):2038\u201349. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.020226.","journal-title":"Circulation"},{"issue":"1","key":"587_CR110","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12933-019-0892-3","volume":"18","author":"GM Uddin","year":"2019","unstructured":"Uddin GM, Zhang L, Shah S, Fukushima A, Wagg CS, Gopal K, et al. Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure. Cardiovasc Diabetol. 2019;18(1):86. https:\/\/doi.org\/10.1186\/s12933-019-0892-3.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"587_CR111","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1161\/CIRCULATIONAHA.115.017545","volume":"133","author":"KC Bedi","year":"2016","unstructured":"Bedi KC, Snyder NW, Brandimarto J, Aziz M, Mesaros C, Worth AJ, et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation. 2016;133(8):706\u201316. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.017545.","journal-title":"Circulation"},{"issue":"11","key":"587_CR112","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1093\/cvr\/cvz045","volume":"115","author":"KL Ho","year":"2019","unstructured":"Ho KL, Zhang L, Wagg C, Al Batran R, Gopal K, Levasseur J, et al. Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency. Cardiovasc Res. 2019;115(11):1606\u201316. https:\/\/doi.org\/10.1093\/cvr\/cvz045.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"587_CR113","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152","volume":"13","author":"J Kim","year":"2011","unstructured":"Kim J, Kundu M, Viollet B, Guan K-L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13(2):132\u201341. https:\/\/doi.org\/10.1038\/ncb2152.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"587_CR114","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.cmet.2013.07.002","volume":"18","author":"G Karamanlidis","year":"2013","unstructured":"Karamanlidis G, Lee CF, Garcia-Menendez L, Kolwicz SC, Suthammarak W, Gong G, et al. Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metab. 2013;18(2):239\u201350. https:\/\/doi.org\/10.1016\/j.cmet.2013.07.002.","journal-title":"Cell Metab"},{"issue":"4","key":"587_CR115","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00395-015-0493-6","volume":"110","author":"C Koentges","year":"2015","unstructured":"Koentges C, Pfeil K, Schnick T, Wiese S, Dahlbock R, Cimolai MC, et al. SIRT3 deficiency impairs mitochondrial and contractile function in the heart. Basic Res Cardiol. 2015;110(4):36. https:\/\/doi.org\/10.1007\/s00395-015-0493-6.","journal-title":"Basic Res Cardiol"},{"issue":"2","key":"587_CR116","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41401-020-0490-7","volume":"42","author":"S Song","year":"2021","unstructured":"Song S, Ding Y, Dai G, Zhang Y, Xu M, Shen J, et al. Sirtuin 3 deficiency exacerbates diabetic cardiomyopathy via necroptosis enhancement and NLRP3 activation. Acta Pharmacol Sin. 2021;42(2):230\u201341. https:\/\/doi.org\/10.1038\/s41401-020-0490-7.","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"587_CR117","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018913","volume":"10","author":"L Li","year":"2021","unstructured":"Li L, Zeng H, He X, Chen J. Sirtuin 3 alleviates diabetic cardiomyopathy by regulating TIGAR and cardiomyocyte metabolism. J Am Heart Assoc. 2021;10(5):e018913. https:\/\/doi.org\/10.1161\/JAHA.120.018913.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"587_CR118","doi-asserted-by":"publisher","first-page":"914","DOI":"10.18632\/aging.100252","volume":"2","author":"AV Hafner","year":"2010","unstructured":"Hafner AV, Dai J, Gomes AP, Xiao C-Y, Palmeira CM, Rosenzweig A, et al. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany NY). 2010;2(12):914\u201323. https:\/\/doi.org\/10.18632\/aging.100252.","journal-title":"Aging (Albany NY)"},{"issue":"9","key":"587_CR119","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.3390\/ijms12096226","volume":"12","author":"S-H Park","year":"2011","unstructured":"Park S-H, Ozden O, Jiang H, Cha YI, Pennington JD, Aykin-Burns N, et al. Sirt3, mitochondrial ROS, ageing, and carcinogenesis. Int J Mol Sci. 2011;12(9):6226\u201339. https:\/\/doi.org\/10.3390\/ijms12096226.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"587_CR120","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/j.scib.2021.04.008","volume":"66","author":"L Ma","year":"2021","unstructured":"Ma L, Shi H, Li Y, Gao W, Guo J, Zhu J, et al. Hypertrophic preconditioning attenuates myocardial ischemia\/reperfusion injury through the deacetylation of isocitrate dehydrogenase 2. Sci Bull (Beijing). 2021;66(20):2099\u2013114. https:\/\/doi.org\/10.1016\/j.scib.2021.04.008.","journal-title":"Sci Bull (Beijing)"},{"issue":"5","key":"587_CR121","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1074\/jbc.M109.077271","volume":"285","author":"VB Pillai","year":"2010","unstructured":"Pillai VB, Sundaresan NR, Kim G, Gupta M, Rajamohan SB, Pillai JB, et al. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J Biol Chem. 2010;285(5):3133\u201344. https:\/\/doi.org\/10.1074\/jbc.M109.077271.","journal-title":"J Biol Chem"},{"key":"587_CR122","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.lfs.2017.07.030","volume":"186","author":"X Guo","year":"2017","unstructured":"Guo X, Yan F, Shan X, Li J, Yang Y, Zhang J, et al. SIRT3 inhibits ang II-induced transdifferentiation of cardiac fibroblasts through \u03b2-catenin\/PPAR-\u03b3 signaling. Life Sci. 2017;186:111\u20137. https:\/\/doi.org\/10.1016\/j.lfs.2017.07.030.","journal-title":"Life Sci"},{"issue":"7","key":"587_CR123","first-page":"3258","volume":"9","author":"X Guo","year":"2017","unstructured":"Guo X, Yan F, Li J, Zhang C, Bu P. SIRT3 attenuates AngII-induced cardiac fibrosis by inhibiting myofibroblasts transdifferentiation via STAT3-NFATc2 pathway. Am J Transl Res. 2017;9(7):3258\u201369.","journal-title":"Am J Transl Res"},{"issue":"47","key":"587_CR124","doi-asserted-by":"publisher","first-page":"33837","DOI":"10.1074\/jbc.M113.510354","volume":"288","author":"SS Bharathi","year":"2013","unstructured":"Bharathi SS, Zhang Y, Mohsen A-W, Uppala R, Balasubramani M, Schreiber E, et al. Sirtuin 3 (SIRT3) protein regulates long-chain acyl-CoA dehydrogenase by deacetylating conserved lysines near the active site. J Biol Chem. 2013;288(47):33837\u201347. https:\/\/doi.org\/10.1074\/jbc.M113.510354.","journal-title":"J Biol Chem"},{"issue":"6","key":"587_CR125","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.cmet.2010.11.003","volume":"12","author":"T Shimazu","year":"2010","unstructured":"Shimazu T, Hirschey MD, Hua L, Dittenhafer-Reed KE, Schwer B, Lombard DB, et al. SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production. Cell Metab. 2010;12(6):654\u201361. https:\/\/doi.org\/10.1016\/j.cmet.2010.11.003.","journal-title":"Cell Metab"},{"issue":"2","key":"587_CR126","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s11357-022-00695-0","volume":"45","author":"P Li","year":"2023","unstructured":"Li P, Newhardt MF, Matsuzaki S, Eyster C, Pranay A, Peelor FF, et al. The loss of cardiac SIRT3 decreases metabolic flexibility and proteostasis in an age-dependent manner. GeroScience. 2023;45(2):983\u201399. https:\/\/doi.org\/10.1007\/s11357-022-00695-0.","journal-title":"GeroScience"},{"issue":"3","key":"587_CR127","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/FJC.0000000000000877","volume":"76","author":"X Guo","year":"2020","unstructured":"Guo X, Yan F, Li J, Zhang C, Su H, Bu P. SIRT3 ablation deteriorates obesity-related cardiac remodeling by modulating ROS-NF-kB-MCP-1 signaling pathway. J Cardiovasc Pharmacol. 2020;76(3):296\u2013304. https:\/\/doi.org\/10.1097\/FJC.0000000000000877.","journal-title":"J Cardiovasc Pharmacol"},{"key":"587_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellsig.2018.09.009","volume":"53","author":"J Liu","year":"2019","unstructured":"Liu J, Yan W, Zhao X, Jia Q, Wang J, Zhang H, et al. Sirt3 attenuates post-infarction cardiac injury via inhibiting mitochondrial fission and normalization of AMPK-Drp1 pathways. Cell Signal. 2019;53:1\u201313. https:\/\/doi.org\/10.1016\/j.cellsig.2018.09.009.","journal-title":"Cell Signal"},{"issue":"9","key":"587_CR129","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1172\/JCI39162","volume":"119","author":"NR Sundaresan","year":"2009","unstructured":"Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest. 2009;119(9):2758\u201371. https:\/\/doi.org\/10.1172\/JCI39162.","journal-title":"J Clin Invest"},{"issue":"3","key":"587_CR130","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41401-022-00966-8","volume":"44","author":"Z-Y Li","year":"2023","unstructured":"Li Z-Y, Lu G-Q, Lu J, Wang P-X, Zhang X-L, Zou Y, et al. SZC-6, a small-molecule activator of SIRT3, attenuates cardiac hypertrophy in mice. Acta Pharmacol Sin. 2023;44(3):546\u201360. https:\/\/doi.org\/10.1038\/s41401-022-00966-8.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"587_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0114-1","volume":"5","author":"X Palomer","year":"2020","unstructured":"Palomer X, Rom\u00e1n-Azcona MS, Pizarro-Delgado J, Planavila A, Villarroya F, Valenzuela-Alcaraz B, et al. SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation. Signal Transduct Target Ther. 2020;5(1):14. https:\/\/doi.org\/10.1038\/s41392-020-0114-1.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"587_CR132","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1128\/MCB.00586-15","volume":"36","author":"NR Sundaresan","year":"2016","unstructured":"Sundaresan NR, Bindu S, Pillai VB, Samant S, Pan Y, Huang J-Y, et al. SIRT3 blocks aging-associated tissue fibrosis in mice by deacetylating and activating glycogen synthase kinase 3\u03b2. Mol Cell Biol. 2016;36(5):678\u201392. https:\/\/doi.org\/10.1128\/MCB.00586-15.","journal-title":"Mol Cell Biol"},{"issue":"20","key":"587_CR133","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.1128\/MCB.00426-08","volume":"28","author":"NR Sundaresan","year":"2008","unstructured":"Sundaresan NR, Samant SA, Pillai VB, Rajamohan SB, Gupta MP. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol. 2008;28(20):6384\u2013401. https:\/\/doi.org\/10.1128\/MCB.00426-08.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"587_CR134","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s12265-012-9398-z","volume":"5","author":"Y Ma","year":"2012","unstructured":"Ma Y, Halade GV, Lindsey ML. Extracellular matrix and fibroblast communication following myocardial infarction. J Cardiovasc Transl Res. 2012;5(6):848\u201357. https:\/\/doi.org\/10.1007\/s12265-012-9398-z.","journal-title":"J Cardiovasc Transl Res"},{"issue":"17","key":"587_CR135","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/j.jacc.2020.03.024","volume":"75","author":"G Del Monte-Nieto","year":"2020","unstructured":"Del Monte-Nieto G, Fischer JW, Gorski DJ, Harvey RP, Kovacic JC. Basic biology of extracellular matrix in the cardiovascular system, part 1\/4: JACC focus seminar. J Am Coll Cardiol. 2020;75(17):2169\u201388. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.024.","journal-title":"J Am Coll Cardiol"},{"key":"587_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.621644","volume":"8","author":"AC Silva","year":"2020","unstructured":"Silva AC, Pereira C, Fonseca ACRG, Pinto-do-\u00d3 P, Nascimento DS. Bearing my heart: the role of extracellular matrix on cardiac development, homeostasis, and injury response. Front Cell Dev Biol. 2020;8:621644. https:\/\/doi.org\/10.3389\/fcell.2020.621644.","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"587_CR137","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20204185","volume":"41","author":"E Boland","year":"2021","unstructured":"Boland E, Quondamatteo F, Van Agtmael T. The role of basement membranes in cardiac biology and disease. Biosci Rep. 2021;41(8):BSR20204185. https:\/\/doi.org\/10.1042\/BSR20204185.","journal-title":"Biosci Rep"},{"issue":"1","key":"587_CR138","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1161\/CIRCRESAHA.116.303577","volume":"119","author":"SD Prabhu","year":"2016","unstructured":"Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res. 2016;119(1):91\u2013112. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.303577.","journal-title":"Circ Res"},{"issue":"14","key":"587_CR139","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1161\/01.cir.101.14.1729","volume":"101","author":"R Querejeta","year":"2000","unstructured":"Querejeta R, Varo N, L\u00f3pez B, Larman M, Arti\u00f1ano E, Etayo JC, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101(14):1729\u201335. https:\/\/doi.org\/10.1161\/01.cir.101.14.1729.","journal-title":"Circulation"},{"issue":"21","key":"587_CR140","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.196933","volume":"10","author":"KM Buck","year":"2025","unstructured":"Buck KM, Rogers HT, Gregorich ZR, Mann MW, Aballo TJ, Gao Z, et al. Extracellular matrix alterations in chronic ischemic cardiomyopathy revealed by quantitative proteomics. JCI Insight. 2025;10(21):e196933. https:\/\/doi.org\/10.1172\/jci.insight.196933.","journal-title":"JCI Insight"},{"issue":"4","key":"587_CR141","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1152\/physrev.00012.2007","volume":"87","author":"FG Spinale","year":"2007","unstructured":"Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007;87(4):1285\u2013342. https:\/\/doi.org\/10.1152\/physrev.00012.2007.","journal-title":"Physiol Rev"},{"issue":"1","key":"587_CR142","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1755-1536-5-15","volume":"5","author":"D Fan","year":"2012","unstructured":"Fan D, Takawale A, Lee J, Kassiri Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair. 2012;5(1):15. https:\/\/doi.org\/10.1186\/1755-1536-5-15.","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"10","key":"587_CR143","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/13459","volume":"5","author":"S Heymans","year":"1999","unstructured":"Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5(10):1135\u201342. https:\/\/doi.org\/10.1038\/13459.","journal-title":"Nat Med"},{"issue":"1","key":"587_CR144","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/JCI8768","volume":"106","author":"A Ducharme","year":"2000","unstructured":"Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106(1):55\u201362. https:\/\/doi.org\/10.1172\/JCI8768.","journal-title":"J Clin Invest"},{"key":"587_CR145","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jconrel.2023.10.033","volume":"364","author":"A Itzhar","year":"2023","unstructured":"Itzhar A, Yosef G, Eilon-Ashkenazy M, Shmidov Y, Gil H, Lacham-Hartman S, et al. Potent inhibition of MMP-9 by a novel sustained-release platform attenuates left ventricular remodeling following myocardial infarction. J Control Release. 2023;364:246\u201360. https:\/\/doi.org\/10.1016\/j.jconrel.2023.10.033.","journal-title":"J Control Release"},{"issue":"3","key":"587_CR146","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1172\/JCI22304","volume":"115","author":"S Matsumura","year":"2005","unstructured":"Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest. 2005;115(3):599\u2013609. https:\/\/doi.org\/10.1172\/JCI22304.","journal-title":"J Clin Invest"},{"issue":"1","key":"587_CR147","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.carpath.2007.12.012","volume":"18","author":"SWM van den Borne","year":"2009","unstructured":"van den Borne SWM, Cleutjens JPM, Hanemaaijer R, Creemers EE, Smits JFM, Daemen MJAP, et al. Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol. 2009;18(1):37\u201343. https:\/\/doi.org\/10.1016\/j.carpath.2007.12.012.","journal-title":"Cardiovasc Pathol"},{"issue":"8","key":"587_CR148","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1161\/CIRCULATIONAHA.104.516963","volume":"112","author":"S Heymans","year":"2005","unstructured":"Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation. 2005;112(8):1136\u201344. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.516963.","journal-title":"Circulation"},{"issue":"1","key":"587_CR149","doi-asserted-by":"publisher","first-page":"H364","DOI":"10.1152\/ajpheart.00511.2002","volume":"284","author":"EEJM Creemers","year":"2003","unstructured":"Creemers EEJM, Davis JN, Parkhurst AM, Leenders P, Dowdy KB, Hapke E, et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol. 2003;284(1):H364\u201371. https:\/\/doi.org\/10.1152\/ajpheart.00511.2002.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"587_CR150","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1161\/HYPERTENSIONAHA.117.09045","volume":"69","author":"A Takawale","year":"2017","unstructured":"Takawale A, Zhang P, Patel VB, Wang X, Oudit G, Kassiri Z. Tissue inhibitor of matrix metalloproteinase-1 promotes myocardial fibrosis by mediating CD63-integrin \u03b21 interaction. Hypertension. 2017;69(6):1092\u2013103. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.09045.","journal-title":"Hypertension"},{"key":"587_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109889","volume":"79","author":"LS Neff","year":"2021","unstructured":"Neff LS, Bradshaw AD. Cross your heart? Collagen cross-links in cardiac health and disease. Cell Signal. 2021;79:109889. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109889.","journal-title":"Cell Signal"},{"issue":"3","key":"587_CR152","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jacc.2015.10.063","volume":"67","author":"B L\u00f3pez","year":"2016","unstructured":"L\u00f3pez B, Ravassa S, Gonz\u00e1lez A, Zubillaga E, Bonavila C, Berg\u00e9s M, et al. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure. J Am Coll Cardiol. 2016;67(3):251\u201360. https:\/\/doi.org\/10.1016\/j.jacc.2015.10.063.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"587_CR153","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.bbamcr.2019.06.001","volume":"1866","author":"A Gonz\u00e1lez","year":"2019","unstructured":"Gonz\u00e1lez A, L\u00f3pez B, Ravassa S, San Jos\u00e9 G, D\u00edez J. The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking. Biochim Biophys Acta Mol Cell Res. 2019;1866(9):1421\u201332. https:\/\/doi.org\/10.1016\/j.bbamcr.2019.06.001.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"12","key":"587_CR154","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121483","volume":"8","author":"C Rodr\u00edguez","year":"2019","unstructured":"Rodr\u00edguez C, Mart\u00ednez-Gonz\u00e1lez J. The role of lysyl oxidase enzymes in cardiac function and remodeling. Cells. 2019;8(12):1483. https:\/\/doi.org\/10.3390\/cells8121483.","journal-title":"Cells"},{"issue":"1","key":"587_CR155","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/cvr\/cvv214","volume":"109","author":"J Gonz\u00e1lez-Santamar\u00eda","year":"2016","unstructured":"Gonz\u00e1lez-Santamar\u00eda J, Villalba M, Busnadiego O, L\u00f3pez-Ola\u00f1eta MM, Sandoval P, Snabel J, et al. Matrix cross-linking lysyl oxidases are induced in response to myocardial infarction and promote cardiac dysfunction. Cardiovasc Res. 2016;109(1):67\u201378. https:\/\/doi.org\/10.1093\/cvr\/cvv214.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"587_CR156","doi-asserted-by":"publisher","first-page":"H2587","DOI":"10.1152\/ajpheart.00516.2003","volume":"285","author":"J Liu","year":"2003","unstructured":"Liu J, Masurekar MR, Vatner DE, Jyothirmayi GN, Regan TJ, Vatner SF, et al. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol. 2003;285(6):H2587\u201391. https:\/\/doi.org\/10.1152\/ajpheart.00516.2003.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"587_CR157","doi-asserted-by":"publisher","first-page":"e0281320","DOI":"10.1371\/journal.pone.0281320","volume":"18","author":"DGF Al-U\u2019datt","year":"2023","unstructured":"Al-U\u2019datt DGF, Tranchant CC, Al-Husein B, Hiram R, Al-Dwairi A, AlQudah M, et al. Involvement and possible role of transglutaminases 1 and 2 in mediating fibrotic signalling, collagen cross-linking and cell proliferation in neonatal rat ventricular fibroblasts. PLoS One. 2023;18(2):e0281320. https:\/\/doi.org\/10.1371\/journal.pone.0281320.","journal-title":"PLoS One"},{"issue":"5","key":"587_CR158","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrm809","volume":"3","author":"JJ Tomasek","year":"2002","unstructured":"Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3(5):349\u201363. https:\/\/doi.org\/10.1038\/nrm809.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"587_CR159","doi-asserted-by":"publisher","first-page":"8345","DOI":"10.1002\/jcp.29678","volume":"235","author":"L Niu","year":"2020","unstructured":"Niu L, Jia Y, Wu M, Liu H, Feng Y, Hu Y, et al. Matrix stiffness controls cardiac fibroblast activation through regulating YAP via AT1 R. J Cell Physiol. 2020;235(11):8345\u201357. https:\/\/doi.org\/10.1002\/jcp.29678.","journal-title":"J Cell Physiol"},{"issue":"1","key":"587_CR160","doi-asserted-by":"publisher","first-page":"17015","DOI":"10.1038\/s41598-024-67646-x","volume":"14","author":"Y Han","year":"2024","unstructured":"Han Y, Shao Z, Zhang Y, Zhao H, Sun Z, Yang C, et al. 3D matrix stiffness modulation unveils cardiac fibroblast phenotypic switching. Sci Rep. 2024;14(1):17015. https:\/\/doi.org\/10.1038\/s41598-024-67646-x.","journal-title":"Sci Rep"},{"key":"587_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101194","volume":"93","author":"S Ravassa","year":"2023","unstructured":"Ravassa S, L\u00f3pez B, Treibel TA, San Jos\u00e9 G, Losada-Fuentenebro B, Tapia L, et al. Cardiac fibrosis in heart failure: focus on non-invasive diagnosis and emerging therapeutic strategies. Mol Aspects Med. 2023;93:101194. https:\/\/doi.org\/10.1016\/j.mam.2023.101194.","journal-title":"Mol Aspects Med"},{"key":"587_CR162","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.926378","volume":"9","author":"L Zhu","year":"2022","unstructured":"Zhu L, Wang Y, Zhao S, Lu M. Detection of myocardial fibrosis: where we stand. Front Cardiovasc Med. 2022;9:926378. https:\/\/doi.org\/10.3389\/fcvm.2022.926378.","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"587_CR163","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.cardfail.2015.12.016","volume":"22","author":"IN Mansour","year":"2016","unstructured":"Mansour IN, Bress AP, Groo V, Ismail S, Wu G, Patel SR, et al. Circulating procollagen type III N-terminal peptide and mortality risk in African Americans with heart failure. J Card Fail. 2016;22(9):692\u20139. https:\/\/doi.org\/10.1016\/j.cardfail.2015.12.016.","journal-title":"J Card Fail"},{"key":"587_CR164","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fphys.2015.00200","volume":"6","author":"ES Lepoj\u00e4rvi","year":"2015","unstructured":"Lepoj\u00e4rvi ES, Piira O-P, P\u00e4\u00e4kk\u00f6 E, Lammentausta E, Risteli J, Miettinen JA, et al. Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties. Front Physiol. 2015;6:200. https:\/\/doi.org\/10.3389\/fphys.2015.00200.","journal-title":"Front Physiol"},{"issue":"4","key":"587_CR165","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ejhf.246","volume":"17","author":"B L\u00f3pez","year":"2015","unstructured":"L\u00f3pez B, Gonz\u00e1lez A, Querejeta R, Zubillaga E, Larman M, D\u00edez J. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur J Heart Fail. 2015;17(4):385\u201392. https:\/\/doi.org\/10.1002\/ejhf.246.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"587_CR166","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jacc.2013.07.087","volume":"63","author":"A Bayes-Genis","year":"2014","unstructured":"Bayes-Genis A, de Antonio M, Vila J, Pe\u00f1afiel J, Gal\u00e1n A, Barallat J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2014;63(2):158\u201366. https:\/\/doi.org\/10.1016\/j.jacc.2013.07.087.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"587_CR167","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12265-017-9775-8","volume":"11","author":"CCS Tseng","year":"2018","unstructured":"Tseng CCS, Huibers MMH, van Kuik J, de Weger RA, Vink A, de Jonge N. The interleukin-33\/ST2 pathway is expressed in the failing human heart and associated with pro-fibrotic remodeling of the myocardium. J Cardiovasc Transl Res. 2018;11(1):15\u201321. https:\/\/doi.org\/10.1007\/s12265-017-9775-8.","journal-title":"J Cardiovasc Transl Res"},{"issue":"12","key":"587_CR168","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1016\/j.jcmg.2021.01.027","volume":"14","author":"S Gupta","year":"2021","unstructured":"Gupta S, Ge Y, Singh A, Gr\u00e4ni C, Kwong RY. Multimodality imaging assessment of myocardial fibrosis. JACC Cardiovasc Imaging. 2021;14(12):2457\u201369. https:\/\/doi.org\/10.1016\/j.jcmg.2021.01.027.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11 Pt 2","key":"587_CR169","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.jcmg.2019.06.031","volume":"12","author":"AA Robinson","year":"2019","unstructured":"Robinson AA, Chow K, Salerno M. Myocardial T1 and ECV measurement: underlying concepts and technical considerations. JACC Cardiovasc Imaging. 2019;12(11 Pt 2):2332\u201344. https:\/\/doi.org\/10.1016\/j.jcmg.2019.06.031.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"587_CR170","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.jcmg.2024.07.011","volume":"18","author":"OA Smiseth","year":"2025","unstructured":"Smiseth OA, Rider O, Cvijic M, Valkovi\u010d L, Remme EW, Voigt JU. Myocardial strain imaging: theory, current practice, and the future. JACC Cardiovasc Imaging. 2025;18(3):340\u201381. https:\/\/doi.org\/10.1016\/j.jcmg.2024.07.011.","journal-title":"JACC Cardiovasc Imaging"},{"key":"587_CR171","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1479777","volume":"11","author":"Q Wu","year":"2024","unstructured":"Wu Q, Song J, Liu W, Li L, Li S. Recent advances in positron emission tomography for detecting early fibrosis after myocardial infarction. Front Cardiovasc Med. 2024;11:1479777. https:\/\/doi.org\/10.3389\/fcvm.2024.1479777.","journal-title":"Front Cardiovasc Med"},{"key":"587_CR172","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.921724","volume":"9","author":"Z Lyu","year":"2022","unstructured":"Lyu Z, Han W, Zhao H, Jiao Y, Xu P, Wang Y, et al. A clinical study on relationship between visualization of cardiac fibroblast activation protein activity by Al18F-NOTA-FAPI-04 positron emission tomography and cardiovascular disease. Front Cardiovasc Med. 2022;9:921724. https:\/\/doi.org\/10.3389\/fcvm.2022.921724.","journal-title":"Front Cardiovasc Med"},{"key":"587_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.nuclcard.2024.102106","volume":"47","author":"K Loganath","year":"2025","unstructured":"Loganath K, Craig N, Barton A, Joshi S, Anagnostopoulos C, Erba PA, et al. Cardiovascular positron emission tomography imaging of fibroblast activation: a review of the current literature. J Nucl Cardiol. 2025;47:102106. https:\/\/doi.org\/10.1016\/j.nuclcard.2024.102106.","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"587_CR174","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s40291-025-00778-6","volume":"29","author":"L Filippi","year":"2025","unstructured":"Filippi L, Perrone MA, Schillaci O. FAPI-targeted molecular imaging: Transforming insights into post-ischemic myocardial remodeling? Mol Diagn Ther. 2025;29(4):435\u201342. https:\/\/doi.org\/10.1007\/s40291-025-00778-6.","journal-title":"Mol Diagn Ther"},{"issue":"6","key":"587_CR175","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jacc.2024.10.103","volume":"85","author":"AK Barton","year":"2025","unstructured":"Barton AK, Craig NJ, Loganath K, Joshi S, Tsampasian V, Mahendran M, et al. Myocardial fibroblast activation after acute myocardial infarction: A positron emission tomography and magnetic resonance study. J Am Coll Cardiol. 2025;85(6):578\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2024.10.103.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"587_CR176","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.123.015490","volume":"17","author":"B Bae\u00dfler","year":"2024","unstructured":"Bae\u00dfler B, Engelhardt S, Hekalo A, Hennemuth A, H\u00fcllebrand M, Laube A, et al. Perfect match: radiomics and artificial intelligence in cardiac imaging. Circ Cardiovasc Imaging. 2024;17(6):e015490. https:\/\/doi.org\/10.1161\/CIRCIMAGING.123.015490.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"587_CR177","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12968-022-00869-x","volume":"24","author":"AS Fahmy","year":"2022","unstructured":"Fahmy AS, Rowin EJ, Arafati A, Al-Otaibi T, Maron MS, Nezafat R. Radiomics and deep learning for myocardial scar screening in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2022;24(1):40. https:\/\/doi.org\/10.1186\/s12968-022-00869-x.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"5","key":"587_CR178","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jcmg.2019.06.030","volume":"13","author":"TD Karamitsos","year":"2020","unstructured":"Karamitsos TD, Arvanitaki A, Karvounis H, Neubauer S, Ferreira VM. Myocardial tissue characterization and fibrosis by imaging. JACC Cardiovasc Imaging. 2020;13(5):1221\u201334. https:\/\/doi.org\/10.1016\/j.jcmg.2019.06.030.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"587_CR179","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.121.013745","volume":"15","author":"W Chen","year":"2022","unstructured":"Chen W, Doeblin P, Al-Tabatabaee S, Klingel K, Tanacli R, Jakob Wei\u00df K, et al. Synthetic extracellular volume in cardiac magnetic resonance without blood sampling: a reliable tool to replace conventional extracellular volume. Circ Cardiovasc Imaging. 2022;15(4):e013745. https:\/\/doi.org\/10.1161\/CIRCIMAGING.121.013745.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"10","key":"587_CR180","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1080\/14796678.2025.2527535","volume":"21","author":"N Gupta","year":"2025","unstructured":"Gupta N, Kumar V, Kanwal A. SIRT3 as a potential biomarker and therapeutic target for cardiovascular diseases: A meta-analysis of clinical studies. Future Cardiol. 2025;21(10):779\u201388. https:\/\/doi.org\/10.1080\/14796678.2025.2527535.","journal-title":"Future Cardiol"},{"key":"587_CR181","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.actbio.2023.04.020","volume":"164","author":"X Qin","year":"2023","unstructured":"Qin X, Cai P, Liu C, Chen K, Jiang X, Chen W, et al. Cardioprotective effect of ultrasound-targeted destruction of Sirt3-loaded cationic microbubbles in a large animal model of pathological cardiac hypertrophy. Acta Biomater. 2023;164:604\u201325. https:\/\/doi.org\/10.1016\/j.actbio.2023.04.020.","journal-title":"Acta Biomater"},{"issue":"2","key":"587_CR182","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1089\/rej.2014.1624","volume":"18","author":"MP Wegman","year":"2015","unstructured":"Wegman MP, Guo MH, Bennion DM, Shankar MN, Chrzanowski SM, Goldberg LA, et al. Practicality of intermittent fasting in humans and its effect on oxidative stress and genes related to aging and metabolism. Rejuvenation Res. 2015;18(2):162\u201372. https:\/\/doi.org\/10.1089\/rej.2014.1624.","journal-title":"Rejuvenation Res"},{"key":"587_CR183","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/876943","author":"A Storka","year":"2013","unstructured":"Storka A, F\u00fchrlinger G, Seper M, Wang L, Jew M, Leisser A, et al. E. coli endotoxin modulates the expression of sirtuin proteins in PBMC in humans. Mediators Inflamm. 2013. https:\/\/doi.org\/10.1155\/2013\/876943.","journal-title":"Mediators Inflamm"},{"issue":"3","key":"587_CR184","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/ejhf.1406","volume":"21","author":"RA de Boer","year":"2019","unstructured":"de Boer RA, De Keulenaer G, Bauersachs J, Brutsaert D, Cleland JG, Diez J, et al. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the committee of translational research of the heart failure association (HFA) of the European Society of Cardiology. Eur J Heart Fail. 2019;21(3):272\u201385. https:\/\/doi.org\/10.1002\/ejhf.1406.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"587_CR185","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1172\/JCI117243","volume":"93","author":"M Crabos","year":"1994","unstructured":"Crabos M, Roth M, Hahn AW, Erne P. Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J Clin Invest. 1994;93(6):2372\u20138. https:\/\/doi.org\/10.1172\/JCI117243.","journal-title":"J Clin Invest"},{"issue":"12","key":"587_CR186","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1161\/01.cir.102.12.1388","volume":"102","author":"CG Brilla","year":"2000","unstructured":"Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102(12):1388\u201393. https:\/\/doi.org\/10.1161\/01.cir.102.12.1388.","journal-title":"Circulation"},{"issue":"21","key":"587_CR187","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1161\/01.cir.0000017264.66561.3d","volume":"105","author":"J D\u00edez","year":"2002","unstructured":"D\u00edez J, Querejeta R, L\u00f3pez B, Gonz\u00e1lez A, Larman M, Mart\u00ednez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105(21):2512\u20137. https:\/\/doi.org\/10.1161\/01.cir.0000017264.66561.3d.","journal-title":"Circulation"},{"issue":"2","key":"587_CR188","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.mce.2011.06.014","volume":"350","author":"A McCurley","year":"2012","unstructured":"McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol. 2012;350(2):256\u201365. https:\/\/doi.org\/10.1016\/j.mce.2011.06.014.","journal-title":"Mol Cell Endocrinol"},{"key":"587_CR189","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijcard.2023.01.088","volume":"377","author":"JP Ferreira","year":"2023","unstructured":"Ferreira JP, Cleland JG, Girerd N, Rossignol P, Pellicori P, Cosmi F, et al. Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: pooled analysis of three randomized trials. Int J Cardiol. 2023;377:86\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2023.01.088.","journal-title":"Int J Cardiol"},{"issue":"6","key":"587_CR190","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","volume":"42","author":"JGF Cleland","year":"2021","unstructured":"Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, et al. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u201cOMics\u201d in AGEing (HOMAGE) randomized clinical trial. Eur Heart J. 2021;42(6):684\u201396. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa758.","journal-title":"Eur Heart J"},{"issue":"1","key":"587_CR191","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62203-0","volume":"16","author":"V Lee","year":"2025","unstructured":"Lee V, Dalakoti M, Zheng Q, Toh D-F, Boubertakh R, Bryant JA, et al. Effects of sacubitril\/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial. Nat Commun. 2025;16(1):6981. https:\/\/doi.org\/10.1038\/s41467-025-62203-0.","journal-title":"Nat Commun"},{"issue":"17","key":"587_CR192","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1908655.","journal-title":"N Engl J Med"},{"issue":"2","key":"587_CR193","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ejhf.3101","volume":"26","author":"JP Ferreira","year":"2024","unstructured":"Ferreira JP, Butler J, Anker SD, Januzzi JL, Panova-Noeva M, Reese-Petersen AL, et al. Effects of empagliflozin on collagen biomarkers in patients with heart failure: findings from the EMPEROR trials. Eur J Heart Fail. 2024;26(2):274\u201384. https:\/\/doi.org\/10.1002\/ejhf.3101.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"587_CR194","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1186\/s40001-025-02834-7","volume":"30","author":"A Albulushi","year":"2025","unstructured":"Albulushi A, Askari KM, Al-Abedi AM, Al-Kulaibi MA, Hasan MS, Hosseini Z, et al. Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study. Eur J Med Res. 2025;30(1):592. https:\/\/doi.org\/10.1186\/s40001-025-02834-7.","journal-title":"Eur J Med Res"},{"issue":"8","key":"587_CR195","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41591-021-01452-0","volume":"27","author":"GA Lewis","year":"2021","unstructured":"Lewis GA, Dodd S, Clayton D, Bedson E, Eccleson H, Schelbert EB, et al. Pirfenidone in heart failure with preserved ejection fraction: A randomized phase 2 trial. Nat Med. 2021;27(8):1477\u201382. https:\/\/doi.org\/10.1038\/s41591-021-01452-0.","journal-title":"Nat Med"},{"issue":"1","key":"587_CR196","doi-asserted-by":"publisher","first-page":"22653","DOI":"10.1038\/s41598-025-06312-2","volume":"15","author":"L Perryman","year":"2025","unstructured":"Perryman L, Findlay A, Baskar J, Charlton B, Foot J, Hamilton R, et al. The small molecule LOXL2 inhibitor SNT-5382 reduces cardiac fibrosis and achieves strong clinical target engagement. Sci Rep. 2025;15(1):22653. https:\/\/doi.org\/10.1038\/s41598-025-06312-2.","journal-title":"Sci Rep"},{"issue":"8","key":"587_CR197","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/eurjhf\/hfr067","volume":"13","author":"JWL Hartog","year":"2011","unstructured":"Hartog JWL, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, et al. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail. 2011;13(8):899\u2013908. https:\/\/doi.org\/10.1093\/eurjhf\/hfr067.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"587_CR198","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41419-018-0573-2","volume":"9","author":"Z Wang","year":"2018","unstructured":"Wang Z, Stuckey DJ, Murdoch CE, Camelliti P, Lip GYH, Griffin M. Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor. Cell Death Dis. 2018;9(6):613. https:\/\/doi.org\/10.1038\/s41419-018-0573-2.","journal-title":"Cell Death Dis"},{"issue":"7774","key":"587_CR199","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, et al. Targeting cardiac fibrosis with engineered T cells. Nature. 2019;573(7774):430\u20133. https:\/\/doi.org\/10.1038\/s41586-019-1546-z.","journal-title":"Nature"},{"issue":"6576","key":"587_CR200","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tomb\u00e1cz I, Yadegari A, M\u00e9ndez Fern\u00e1ndez PO, Shewale SV, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91\u20136. https:\/\/doi.org\/10.1126\/science.abm0594.","journal-title":"Science"},{"issue":"1","key":"587_CR201","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1161\/CIRCRESAHA.124.325017","volume":"136","author":"S Yoshida","year":"2025","unstructured":"Yoshida S, Hayashi H, Kawahara T, Katsuki S, Kimura M, Hino R, et al. A vaccine against fibroblast activation protein improves murine cardiac fibrosis by preventing the accumulation of myofibroblasts. Circ Res. 2025;136(1):26\u201340. https:\/\/doi.org\/10.1161\/CIRCRESAHA.124.325017.","journal-title":"Circ Res"},{"issue":"1","key":"587_CR202","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1038\/s41467-025-56703-2","volume":"16","author":"H Chen","year":"2025","unstructured":"Chen H, Hu K, Tang Q, Wang J, Gu Q, Chen J, et al. CD248-targeted BBIR-T cell therapy against late-activated fibroblasts in cardiac repair after myocardial infarction. Nat Commun. 2025;16(1):2895. https:\/\/doi.org\/10.1038\/s41467-025-56703-2.","journal-title":"Nat Commun"},{"issue":"1","key":"587_CR203","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41392-024-01816-1","volume":"9","author":"F Peng","year":"2024","unstructured":"Peng F, Liao M, Jin W, Liu W, Li Z, Fan Z, et al. 2-APQC, a small-molecule activator of sirtuin-3 (SIRT3), alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis. Signal Transduct Target Ther. 2024;9(1):133. https:\/\/doi.org\/10.1038\/s41392-024-01816-1.","journal-title":"Signal Transduct Target Ther"},{"key":"587_CR204","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.813272","volume":"13","author":"GZ Liu","year":"2022","unstructured":"Liu GZ, Xu W, Zang YX, Lou Q, Hang PZ, Gao Q, et al. Honokiol inhibits atrial metabolic remodeling in atrial fibrillation through Sirt3 pathway. Front Pharmacol. 2022;13:813272. https:\/\/doi.org\/10.3389\/fphar.2022.813272.","journal-title":"Front Pharmacol"},{"key":"587_CR205","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1038\/ncomms7656","volume":"6","author":"VB Pillai","year":"2015","unstructured":"Pillai VB, Samant S, Sundaresan NR, Raghuraman H, Kim G, Bonner MY, et al. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nat Commun. 2015;6:6656. https:\/\/doi.org\/10.1038\/ncomms7656.","journal-title":"Nat Commun"},{"key":"587_CR206","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.151957","volume":"770","author":"M Wu","year":"2025","unstructured":"Wu M, Chen G, Peng Y, Luo S. Alleviation of fibrosis and oxidative stress in pressure overload-induced cardiac remodeling and heart failure via SIRT3 activation by colchicine. Biochem Biophys Res Commun. 2025;770:151957. https:\/\/doi.org\/10.1016\/j.bbrc.2025.151957.","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"587_CR207","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.jacbts.2022.06.012","volume":"7","author":"DD Wang","year":"2022","unstructured":"Wang DD, Airhart SE, Zhou B, Shireman LM, Jiang S, Melendez Rodriguez C, et al. Safety and tolerability of nicotinamide riboside in heart failure with reduced ejection fraction. JACC Basic Transl Sci. 2022;7(12):1183\u201396. https:\/\/doi.org\/10.1016\/j.jacbts.2022.06.012.","journal-title":"JACC Basic Transl Sci"},{"key":"587_CR208","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104863","volume":"98","author":"K Qian","year":"2023","unstructured":"Qian K, Tang J, Ling Y-J, Zhou M, Yan X-X, Xie Y, et al. Exogenous NADPH exerts a positive inotropic effect and enhances energy metabolism via SIRT3 in pathological cardiac hypertrophy and heart failure. EBioMedicine. 2023;98:104863. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104863.","journal-title":"EBioMedicine"},{"key":"587_CR209","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.pharmthera.2018.03.004","volume":"188","author":"H Dai","year":"2018","unstructured":"Dai H, Sinclair DA, Ellis JL, Steegborn C. Sirtuin activators and inhibitors: promises, achievements, and challenges. Pharmacol Ther. 2018;188:140\u201354. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.03.004.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"587_CR210","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1161\/CIRCRESAHA.124.323892","volume":"134","author":"N Cadosch","year":"2024","unstructured":"Cadosch N, Gil-Cruz C, Perez-Shibayama C, Ludewig B. Cardiac fibroblastic niches in homeostasis and inflammation. Circ Res. 2024;134(12):1703\u201317. https:\/\/doi.org\/10.1161\/CIRCRESAHA.124.323892.","journal-title":"Circ Res"},{"issue":"19","key":"587_CR211","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1093\/eurheartj\/ehaf902","volume":"47","author":"S Van Linthout","year":"2026","unstructured":"Van Linthout S, Matz I, Gonz\u00e1lez A, Davis J. Cardiac fibroblasts in myocardial injury and heart failure. Eur Heart J. 2026;47(19):2271\u201385. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf902.","journal-title":"Eur Heart J"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00587-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00587-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00587-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:04:07Z","timestamp":1789527847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00587-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":211,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["587"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00587-1","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"170"}}